Search

Surgical nerve decompression, used to treat conditions such as carpal tunnel syndrome and sciatica, could play a role in relieving the pain of diabetic neuropathy patients, researchers at UT Southwestern Medical Center found.

Researchers at UT Southwestern announced successful results of a clinical trial for a commonly prescribed weight-loss drug called liraglutide.

Researchers have long known that outcomes for alcohol-associated liver disease (ALD) aren’t equal among all races and ethnicities in the U.S., but differences among these groups have been less clear.

As weight-loss drugs capture the public’s imagination, UTSW and its Nutrition Obesity Research Center are uniquely positioned to lead the way in discovery, education, and community outreach.

UT Southwestern is notifying patients treated by UT Southwestern physicians of improper disclosure of protected health information.

A protein called torsinA plays a key role in the early development of neurons, determining where nuclear pores are placed in the membrane that encloses the nucleus of nerve cells, a study led by UT Southwestern Medical Center researchers shows.

A novel study by UT Southwestern researchers who conducted interviews as the nation shut down due to COVID-19 tells the stories of those who routinely faced hunger before the pandemic upended their lives.

For decades, researchers have assumed that women taking oral contraceptives have stable levels of sex hormones over each monthly cycle. However, a new study in the American Journal of Physiology-Endocrinology and Metabolism led by Yasin Dhaher, Ph.D., Professor of Physical Medicine & Rehabilitation

Breastfeeding secures delivery of sugar and fat for milk production by changing the insulin sensitivity of organs that supply or demand these nutrients, a new study led by UT Southwestern scientists suggests.

Millions of children have food allergies, many of which can cause severe illness or death. In a study published in the New England Journal of Medicine, a team of researchers, including those from UT Southwestern, shows in a phase three clinical trial that an antibody-based therapy called omalizumab